Nanoscope Therapeutics Begins FDA Rolling Submission for MCO-010 in Retinitis Pigmentosa
Nanoscope Therapeutics has initiated a rolling submission of its Biologics License Application (BLA) to the FDA for MCO-010, a first-in-class, gene-agnostic optogenetic therapy targeting severe vision loss due to retinitis pigmentosa (RP). The therapy, delivered through a single, in-office intravitreal injection, is designed to restore vision in patients regardless of their underlying genetic mutation. Full submission of the BLA is expected by early 2026, and the application is eligible for priority review under the therapy’s fast-track designation.
“For the first time, pat...
